Table 3 Between-group differences in changes at week 24 for clinical measures of interest in subgroups stratified by baseline serum insulin concentration
Parameter | Treatment effect measures | Baseline serum insulin concentration < 7.5 mU/L | Baseline serum insulin concentration ≥ 7.5 mU/L | p-value for interaction |
|---|---|---|---|---|
SBP, mmHg | Difference (canagliflozin minus glimepiride) in change | 3.082 (− 2.423 to 8.587) | − 1.621 (− 7.026 to 3.784) | 0.232 |
BMI, kg/m2 | − 0.933 (− 1.474 to − 0.393) | − 1.590 (− 2.130 to − 1.050) | 0.092 | |
ePV, % | − 6.500 (− 12.933 to − 0.066) | − 7.477 (− 13.847 to − 1.106) | 0.832 | |
eGFR, mL/min/1.73m2 | 0.679 (− 2.552 to 3.910) | − 1.736 (− 4.938 to 1.465) | 0.298 | |
HbA1c, % | 0.229 (− 0.055 to 0.513) | 0.498 (0.214 to 0.782) | 0.189 | |
Uric acid, mg/dL | − 1.057 (− 1.485 to − 0.655) | − 0.859 (− 1.266 to − 0.452) | 0.498 | |
Triglycerides, mg/dL | 0.372 (− 29.247 to 29.990) | 4.462 (− 25.061 to 33.985) | 0.848 | |
HDL-C, mg/dL | 4.559 (1.366 to 7.752) | 1.812 (− 1.352 to 4.976) | 0.231 | |
LDL-C, mg/dL | 0.924 (− 7.180 to 9.029) | 5.555 (− 2.498 to 13.608) | 0.427 | |
NT-proBNP* | Ratio (canagliflozin vs. glimepiride) of proportional change | 0.946 (0.752 to 1.190) | 0.977 (0.782 to 1.222) | 0.840 |